GLP1R and obesity disorder: Probably, GLP-1R agonism could be a competent therapeutic strategy to combat obesity-related diabetes with minimal side effects (such as nausea and vomiting), also because of its beneficial effects on the nervous and cardiovascular systems and metabolic equilibrium (Zhao et al., 2021).